Three-drug combination active in pretreated multiple myeloma

NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.The regimen — which consisted of teclistamab (JNJ-64007957, Janssen), subcutaneous daratumumab...

Myeloma Heroes Come in Many Forms

Source: Cure Today articles I find myself enormously inadequate to fully explain why I think this lady, my wife, should be selected as a Multiple Myeloma Hero, but whether she is or not, she is my hero. Read More

Stopping Myeloma at the Start

Source: Cure Today articles Even with all he has already done, Dr. Landgren continues to study the progression of multiple myeloma, with the goal of stopping progression and finding a cure. Read More